Skip to content

U-100 unit conversion

Tirzepatide calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

5U-100 units · 0.05 mL

50 mcg per unit · 5000 mcg/mL

How the calculator works, sources and review dates

Tirzepatide math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 10 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-12. source-curated; clinician review pending.

Units chart for listed Tirzepatide sizes

U-100 math for listed Tirzepatide sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
10 mg1005033.3
30 mg300150100

What is Tirzepatide?

Other names in the library include Zepbound, Mounjaro, T-10, and T-30. Approved-product evidence applies to the labeled pen in DailyMed. A 10 mg or 30 mg research vial is a seller listing. It is not a substitute pen. It does not let you copy the label schedule.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Product label

Approved product label

People meeting labeled weight-management or obstructive-sleep-apnea criteria; other approved products have different indications.

Reported findings. In a 72-week randomized trial of 2,539 adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes, estimated average weight loss was 15.0%, 19.5% and 20.9% in the assigned 5, 10 and 15 mg weekly tirzepatide study groups, versus 3.1% with placebo. Doses increased gradually, and all groups received diet and physical-activity support. These are study results, not dosing advice.

Nonresponse. At least 5% weight loss was reached by 85.1%, 88.9% and 90.9% of the respective treatment groups versus 34.5% with placebo. Some participants did not reach that threshold; group averages do not predict an individual result.

Harms. Gastrointestinal reactions, pancreatitis and dehydration-related kidney injury are among label warnings.

Limits. Labeled preparation only; marketed variants do not inherit approval. This result concerns the studied subcutaneous preparation and population; it does not establish equivalence of compounded or research products. Missing week-72 weights were estimated in the analysis. Weight change does not establish a food-noise or personal quality-of-life benefit.

Preparation: Zepbound; Mounjaro is a separate labeled product. Route: subcutaneous

Read original source ↗

Editorial review 2026-10-12. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

approved product. Zepbound; Mounjaro is a separate labeled product.

Compounding

not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.

Research

product specific. People meeting labeled weight-management or obstructive-sleep-apnea criteria; other approved products have different indications.

Sport

unknown. Not individually verified; consult your sport authority.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. The current Zepbound label reports approximately 5–6 days; no falsely precise single value is supplied.

The vendor file lists 10 mg and 30 mg research sizes. Approved pens have their own storage carton. Keep those instructions separate.

Risks and mix-ups already on the record

  • Gastrointestinal reactions, pancreatitis and dehydration-related kidney injury are among label warnings.
  • Personal or family medullary thyroid carcinoma, MEN2, or serious hypersensitivity: see the full product label.
  • Insulin and sulfonylureas can increase hypoglycemia risk; delayed gastric emptying can affect oral medicines.
  • The label warns of reduced oral hormonal contraceptive efficacy; discuss alternative or additional contraception with the prescribing clinician.

People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.

Sources

  1. Approved product label · checked 2026-10-09
  2. Zepbound DailyMed label · checked 2026-10-09
  3. SURMOUNT-1 (PubMed 36356202) · checked 2026-10-09
  4. FDA concerns about unapproved GLP-1 drugs · checked 2026-10-09

Questions people ask

Is a research tirzepatide vial the same as Zepbound?

Zepbound is a specific approved product. Research-market vials are not that product. They do not inherit its approval or proven sameness.

Where do the unit numbers come from?

From the mass and liquid you type and a U-100 scale of 100 marks per mL. The page never fills a medical amount.

How many units is a listed Tirzepatide vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.